On November 29, 2023 Taysha Gene Therapies announced that Health Canada has authorized a protocol amendment to the ongoing REVEAL Phase 1/2 adult trial evaluating TSHA-102 that expands eligibility to include patients aged 12 and older with Rett syndrome.